Andrei G Vlassenko1,2,3, Lena McCue4, Mateusz S Jasielec4, Yi Su5, Brian A Gordon5,6, Chengjie Xiong6,4, David M Holtzman7,6,8, Tammie L S Benzinger5,7,6, John C Morris7,6,8, Anne M Fagan7,6,8. 1. Department of Radiology, Washington University School of Medicine, Saint Louis, MO. andrei@npg.wustl.edu. 2. Hope Center for Neurological Disorders, Washington University School of Medicine, Saint Louis, MO. andrei@npg.wustl.edu. 3. Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, MO. andrei@npg.wustl.edu. 4. Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO. 5. Department of Radiology, Washington University School of Medicine, Saint Louis, MO. 6. Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, MO. 7. Hope Center for Neurological Disorders, Washington University School of Medicine, Saint Louis, MO. 8. Department of Neurology, Washington University School of Medicine, Saint Louis, MO.
Abstract
OBJECTIVE: Deposition of amyloid β (Aβ)-containing plaques as evidenced by amyloid imaging and cerebrospinal fluid (CSF) Aβ1-42 (Aβ42) is an early indicator of preclinical Alzheimer disease (AD). To better understand their relationship during the earliest preclinical stages, we investigated baseline CSF markers in cognitively normal individuals at different stages of amyloid deposition defined by longitudinal amyloid imaging with Pittsburgh compound B (PIB): (1) PIB-negative at baseline and follow-up (PIB(-) ; normal), (2) PIB-negative at baseline but PIB-positive at follow-up (PIB converters; early preclinical AD), and (3) PIB-positive at baseline and follow-up (PIB(+) ; preclinical AD). METHODS: Cognitively normal individuals (n = 164) who had undergone baseline PIB scan and CSF collection within 1 year of each other and at least 1 additional PIB follow-up were included. Amyloid status was defined dichotomously using an a priori mean cortical cutoff. RESULTS: PIB converters (n = 20) at baseline exhibited significantly lower CSF Aβ42 compared to those who remained PIB-negative (n = 123), but higher compared to the PIB(+) group (n = 21). A robust negative correlation (r = -0.879, p = 0.0001) between CSF Aβ42 and absolute (but subthreshold) PIB binding was observed during this early preclinical stage. The negative correlation was not as strong once individuals were PIB-positive (r = -0.456, p = 0.038), and there was no correlation in the stable PIB(-) group (p = 0.905) or in the group (n = 10) with early symptomatic AD (p = 0.537). INTERPRETATION: CSF Aβ42 levels are tightly coupled with cortical amyloid load in the earliest stages of preclinical AD, and begin to decrease dramatically prior to the point when an abnormal threshold of cortical accumulation is detected with amyloid imaging. Ann Neurol 2016;80:379-387.
OBJECTIVE: Deposition of amyloid β (Aβ)-containing plaques as evidenced by amyloid imaging and cerebrospinal fluid (CSF) Aβ1-42 (Aβ42) is an early indicator of preclinical Alzheimer disease (AD). To better understand their relationship during the earliest preclinical stages, we investigated baseline CSF markers in cognitively normal individuals at different stages of amyloid deposition defined by longitudinal amyloid imaging with Pittsburgh compound B (PIB): (1) PIB-negative at baseline and follow-up (PIB(-) ; normal), (2) PIB-negative at baseline but PIB-positive at follow-up (PIB converters; early preclinical AD), and (3) PIB-positive at baseline and follow-up (PIB(+) ; preclinical AD). METHODS: Cognitively normal individuals (n = 164) who had undergone baseline PIB scan and CSF collection within 1 year of each other and at least 1 additional PIB follow-up were included. Amyloid status was defined dichotomously using an a priori mean cortical cutoff. RESULTS:PIB converters (n = 20) at baseline exhibited significantly lower CSF Aβ42 compared to those who remained PIB-negative (n = 123), but higher compared to the PIB(+) group (n = 21). A robust negative correlation (r = -0.879, p = 0.0001) between CSF Aβ42 and absolute (but subthreshold) PIB binding was observed during this early preclinical stage. The negative correlation was not as strong once individuals were PIB-positive (r = -0.456, p = 0.038), and there was no correlation in the stable PIB(-) group (p = 0.905) or in the group (n = 10) with early symptomatic AD (p = 0.537). INTERPRETATION: CSF Aβ42 levels are tightly coupled with cortical amyloid load in the earliest stages of preclinical AD, and begin to decrease dramatically prior to the point when an abnormal threshold of cortical accumulation is detected with amyloid imaging. Ann Neurol 2016;80:379-387.
Authors: Andrei G Vlassenko; Mark A Mintun; Chengjie Xiong; Yvette I Sheline; Alison M Goate; Tammie L S Benzinger; John C Morris Journal: Ann Neurol Date: 2011-11 Impact factor: 10.422
Authors: Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe Journal: Ann Neurol Date: 2011-01 Impact factor: 10.422
Authors: J C Morris; K Blennow; L Froelich; A Nordberg; H Soininen; G Waldemar; L-O Wahlund; B Dubois Journal: J Intern Med Date: 2014-03 Impact factor: 8.989
Authors: Courtney L Sutphen; Mateusz S Jasielec; Aarti R Shah; Elizabeth M Macy; Chengjie Xiong; Andrei G Vlassenko; Tammie L S Benzinger; Erik E J Stoops; Hugo M J Vanderstichele; Britta Brix; Heather D Darby; Manu L J Vandijck; Jack H Ladenson; John C Morris; David M Holtzman; Anne M Fagan Journal: JAMA Neurol Date: 2015-09 Impact factor: 18.302
Authors: J E Maggio; E R Stimson; J R Ghilardi; C J Allen; C E Dahl; D C Whitcomb; S R Vigna; H V Vinters; M E Labenski; P W Mantyh Journal: Proc Natl Acad Sci U S A Date: 1992-06-15 Impact factor: 11.205
Authors: Yi Su; Tyler M Blazey; Abraham Z Snyder; Marcus E Raichle; Daniel S Marcus; Beau M Ances; Randall J Bateman; Nigel J Cairns; Patricia Aldea; Lisa Cash; Jon J Christensen; Karl Friedrichsen; Russ C Hornbeck; Angela M Farrar; Christopher J Owen; Richard Mayeux; Adam M Brickman; William Klunk; Julie C Price; Paul M Thompson; Bernadino Ghetti; Andrew J Saykin; Reisa A Sperling; Keith A Johnson; Peter R Schofield; Virginia Buckles; John C Morris; Tammie L S Benzinger Journal: Neuroimage Date: 2014-12-05 Impact factor: 6.556
Authors: Rachel Potter; Bruce W Patterson; Donald L Elbert; Vitaliy Ovod; Tom Kasten; Wendy Sigurdson; Kwasi Mawuenyega; Tyler Blazey; Alison Goate; Robert Chott; Kevin E Yarasheski; David M Holtzman; John C Morris; Tammie L S Benzinger; Randall J Bateman Journal: Sci Transl Med Date: 2013-06-12 Impact factor: 17.956
Authors: Andrei G Vlassenko; Brian A Gordon; Manu S Goyal; Yi Su; Tyler M Blazey; Tony J Durbin; Lars E Couture; Jon J Christensen; Hussain Jafri; John C Morris; Marcus E Raichle; Tammie L-S Benzinger Journal: Neurobiol Aging Date: 2018-03-20 Impact factor: 4.673
Authors: Catherine M Roe; Beau M Ances; Denise Head; Ganesh M Babulal; Sarah H Stout; Elizabeth A Grant; Jason Hassenstab; Chengjie Xiong; David M Holtzman; Tammie L S Benzinger; Suzanne E Schindler; Anne M Fagan; John C Morris Journal: Brain Date: 2018-11-01 Impact factor: 13.501
Authors: Belinda M Brown; Hamid R Sohrabi; Kevin Taddei; Samantha L Gardener; Stephanie R Rainey-Smith; Jeremiah J Peiffer; Chengjie Xiong; Anne M Fagan; Tammie Benzinger; Virginia Buckles; Kirk I Erickson; Roger Clarnette; Tejal Shah; Colin L Masters; Michael Weiner; Nigel Cairns; Martin Rossor; Neill R Graff-Radford; Stephen Salloway; Jonathan Vöglein; Christoph Laske; James Noble; Peter R Schofield; Randall J Bateman; John C Morris; Ralph N Martins Journal: Alzheimers Dement Date: 2017-05-11 Impact factor: 21.566
Authors: Peter R Millar; Beau M Ances; Brian A Gordon; Tammie L S Benzinger; Anne M Fagan; John C Morris; David A Balota Journal: Neurobiol Aging Date: 2020-08-18 Impact factor: 4.673
Authors: Bliss Elizabeth O'Bryhim; Rajendra S Apte; Nathan Kung; Dean Coble; Gregory P Van Stavern Journal: JAMA Ophthalmol Date: 2018-11-01 Impact factor: 7.389
Authors: Erik S Musiek; Meghana Bhimasani; Margaret A Zangrilli; John C Morris; David M Holtzman; Yo-El S Ju Journal: JAMA Neurol Date: 2018-05-01 Impact factor: 18.302